LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

LLY

1,068.18

-0.55%↓

JNJ

223.34

+0.54%↑

ABBV

213.21

+0.63%↑

UNH

375.03

-0.89%↓

MRK

116.08

+1.27%↑

Home・Elenco Azioni・Coherus Oncology Inc

Coherus Oncology Inc

Aperta

SettoreSettore sanitario

1.52 -5.59

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.51

Massimo

1.5899999999999999

Metriche Chiave
By Trading Economics
Entrata	-278M -37M
Vendite	-438K 12M
P/E Media del settore	3.509 50.102
EPS	-0.25
Margine di Profitto	-300.041
Dipendenti	145
EBITDA	7.9M -35M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+425.48% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-11M 248M
Apertura precedente	7.11
Chiusura precedente	1.52

Notizie sul Sentiment di mercato

By Acuity

50%

153 / 344 Classifica in Healthcare

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 giu 2026, 23:38 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 23:01 UTC

Discorsi di Mercato

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 giu 2026, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 giu 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 giu 2026, 21:55 UTC

Acquisizioni, Fusioni, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 giu 2026, 21:53 UTC

Discorsi di Mercato

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 giu 2026, 21:22 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 giu 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

1 giu 2026, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 giu 2026, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 giu 2026, 19:40 UTC

Discorsi di Mercato

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 giu 2026, 19:28 UTC

Discorsi di Mercato

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 giu 2026, 19:01 UTC

Discorsi di Mercato

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 giu 2026, 18:58 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 giu 2026, 18:54 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 giu 2026, 18:33 UTC

Discorsi di Mercato

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 giu 2026, 18:32 UTC

Discorsi di Mercato

Precious Metals Fall to Start June -- Market Talk

1 giu 2026, 18:00 UTC

Acquisizioni, Fusioni, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 giu 2026, 17:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 giu 2026, 17:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

425.48% in crescita

Previsioni per 12 mesi

Media 8.25 USD 425.48%

Alto 12 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

153 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.